Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with next-generation androgen receptor inhibitors. However, direct comparative data are not available to inform treatment decisions and/or guideline recommendations. Therefore, we performed netw...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Keiichiro, Mostafaei, Hadi, Pradere, Benjamin, Motlagh, Reza Sari, Quhal, Fahad, Laukhtina, Ekaterina, Schuettfort, Victor M., Abufaraj, Mohammad, Karakiewicz, Pierre I., Kimura, Takahiro, Egawa, Shin, Shariat, Shahrokh F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572325/
https://www.ncbi.nlm.nih.gov/pubmed/32924096
http://dx.doi.org/10.1007/s10147-020-01777-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572325/
https://www.ncbi.nlm.nih.gov/pubmed/32924096
http://dx.doi.org/10.1007/s10147-020-01777-9

Ejemplares similares